Stockscreener 앱 받기
31.45
4.21%
1.2757
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Australia
What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News
When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News
Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News
What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News
What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News
Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World
Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementTen-Year Sector Performance and Summary Analysis - Newser
William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World
Published on: 2025-08-01 19:39:34 - Newser
Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest
Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser
Citigroup maintains Buy rating on LENZ Therapeutics, raises PT to $49. - AInvest
Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com Canada
LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop - MSN
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia - The Manila Times
FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan
Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool
Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks
Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser
FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN
LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN
Biotech Stocks Under FDA Review in August 2025: LENZ Therapeutics and PharmaTher Holdings - AInvest
LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Australia
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance
How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics and the Imminent FDA Decision for LNZ100: A High-Conviction Biotech Play Ahead of PDUFA - AInvest
LENZ Therapeutics Preps Launch of First Aceclidine Eye Drops: FDA Decision in 9 Days, $195M Global Deals Secured - Stock Titan
0.14%
0.27%
자본화:
|
볼륨(24시간):